N30 Pharmaceuticals appoints Jon Congleton to be president and CEO

N30 Pharmaceuticals appoints Jon Congleton to be president and CEO

BOULDER - N30 Pharmaceuticals Inc. , a clinical-stage, biopharmaceutical company focused on development of therapies for cystic fibrosis, announced its board of directors has appointed Jon... Read More

By: InnovatioNews Tuesday December 23, 2014 0 comments Tags: Boulder, cystic fibrosis, Howard Furst, Jon Congleton, N30 Pharmaceuticals

N30 Pharma picks up $30M in mezzanine funding round to advance cystic fibrosis drug

N30 Pharma picks up $30M in mezzanine funding round to advance cystic fibrosis drug

BOULDER - N30 Pharmaceuticals Inc. , a clinical-stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis, announced it raised $30 million in a mezzanine... Read More

By: InnovatioNews Monday November 24, 2014 0 comments Tags: Boulder, cystic fibrosis, Deerfield Management, Howard Furst, Jennison Associates, N30 Pharmaceuticals, N91115, Sabby Management

N30 Pharmaceuticals treats first patient with investigational cystic fibrosis drug

N30 Pharmaceuticals treats first patient with investigational cystic fibrosis drug

BOULDER - N30 Pharmaceuticals Inc. announced it has administered the first dose in its Phase 1b/2a clinical trial of N6022 in patients with cystic fibrosis. The study is a multi-center,... Read More

By: Steve Friday March 15, 2013 0 comments Tags: Boulder, Charles Scoggin, cystic fibrosis, N30 Pharmaceuticals, N6022